Effects of the non-selective beta-adrenoceptor blocking agent, carteolol, on platelet function, blood coagulation and viscosity.
We have studied the effect of a new beta-adrenergic blocker, carteolol, on platelet function, blood coagulation and viscosity in 10 healthy male volunteers. Following carteolol (5 mg orally) we were able to demonstrate significant inhibition of platelet aggregation to ADP (p less than 0.05) and adrenaline (p less than 0.01) after 5 hours, but not at 2 or 24 hours. This maximum inhibition of platelet aggregation corresponded to peak plasma concentrations of carteolol measured. The platelet release reaction, as measured by plasma levels of the platelet specific protein beta-thromboglobulin (BTG) was unaltered and there was no significant effect on a panel of coagulation tests or on blood viscosity.
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000328:Adult; D001760:Bleeding Time; D001777:Blood Coagulation / Q000187:drug effects*; D001780:Blood Coagulation Tests; D001792:Blood Platelets / Q000187:drug effects*; D001809:Blood Viscosity / Q000187:drug effects*; D002354:Carteolol / Q000097:blood / Q000494:pharmacology*; D002940:Circadian Rhythm / Q000187:drug effects; D003094:Collagen / Q000494:pharmacology; D004837:Epinephrine / Q000494:pharmacology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D011412:Propanolamines / Q000494:pharmacology*; D001620:beta-Thromboglobulin
D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; D001620:beta-Thromboglobulin; D000244:Adenosine Diphosphate; D002354:Carteolol; D003094:Collagen; D004837:Epinephrine